MREO — Mereo BioPharma Share News
0.000.00%
Last trade - 00:00- $44.96m
- $14.85m
- $0.50m
Brief: Rubric Capital Enters Into Letter Agreement With Mereo Biopharma Group Regarding Cooperation Deal
Brief: Adage Capital Partners GP Reports 7.17% Passive Stake In Mereo Biopharma Group As Of Jan 24 - SEC Filing
Brief: Mereo Biopharma Provides Update On Pipeline Progress And Corporate Developments
Brief: Mereo Biopharma Group Says Current Cash Expected To Fund Operations Into 2026
Brief: Mereo Biopharma Group PLC Says It Continues To Seek A Partner For Further Development Of Etigilimab
Ultragenyx Pharma rebounds after $300 mln equity offering priced
Ultragenyx Pharma slides after stock offering launch
Brief: Ultragenyx And Mereo Biopharma Announce Interim Phase 2 Data From Phase 2/3 Orbit Study Demonstrating Setrusumab (Ux143) Significantly Reduced Fracture Rates In Patients With Osteogenesis Imperfecta
Brief: Mereo Biopharma Reports Interim Financial Results For The Six Months Ended June 30, 2023
Cancer drugmakers gain after Roche discloses positive data from drug study
Brief: Ultragenyx Announces First Patients Dosed In Phase 3 Program Evaluating Setrusumab (UX143) For The Treatment Of Osteogenesis Imperfecta
Mereo BioPharma gains on positive data from genetic disorder drug trial
Brief: Ultragenyx, Mereo BioPharma Announces Positive Data From Ongoing Phase 2/3 Orbit Study Of Setrusumab
Brief: Mereo Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Mereo BioPharma Announces Listing Transfer To Nasdaq Capital Market
Brief: Mereo Biopharma Reports Full Year 2022 Financial Results And Recent Highlights
Mereo BioPharma rises on positive FDA meeting for lung disease drug
Brief: Mereo Biopharma Provides Regulatory Updates On Alvelestat For Treatment Of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
RCS - Imophoron Limited - Imophoron appoints Richard Bungay as CEO